Rethinking the Treatment of Pathologic Scars
Journal Title: Biomedical Journal of Scientific & Technical Research (BJSTR) - Year 2019, Vol 13, Issue 2
Abstract
Over 100 million people develop a pathologic scar every year worldwide [1] Attempts to treat scars in the United States alone account for almost $15 Billion of expenditures with a large percentage of patients left with scars so symptomatic and impactful on daily life that they continue to seek treatment [2]. The Scar Free Foundation’s 2015 mandate to deliver scar free healing within a generation is a testament to the magnitude of this problem. Traditional theories about the causes of pathologic scar include fibroblast overgrowth, collagen overproduction, dysfunctional local immune response, presence of poorly encapsulated loose particles, endocrine irregularities, over or underproduction of cytokine mediators and presence of unique inflammatory cells. Recent understanding of the pathophysiology of scar is that it results from failure to progress through the normal phases of healing, from the inflammatory phase to the proliferative phase to the remodeling phase. It remains unknown how the dominant cells of each phase “hand off” to the dominant cells of the next phase and allow the wound to progress without becoming locked into a pro-fibrotic state that cannot resolve itself. In clinical practice, patients arrive with scars of highly variable etiology, time course and symptomatology which makes it impossible to establish rigid research protocols. Current scar treatment protocols include steroid injections, silicone pressure therapy, immunosuppressive agent injections, cryotherapy, surgery, radiation and laser as well as other less common methods. Some non-surgical methods of treatment include compression garments, massage, pulsed light, steroids, exercise and fat injections. The decision of which therapy to apply against a given scar is often the result of the most senior authority’s informed opinion or rigid adherence to an established protocol which accepts variable outcomes. Internationally recognized experts agree that current therapies are “not enough” [3]. Many clinical studies can show improvement on a given scar scale, but there is a persistently low adoption rate of any given protocol into clinical practice. The design of randomized controlled trials to match and compare therapies has been complicated by the wide variation of causal factors, demographics and lapse in time since the original injury. The impact of this level of imprecision and complexity is frustrating to both patients and practitioners alike as they try to match the right scar with the right treatment to get consistent and effective results. What works in one patient scenario may not work in the next. As a result, there exists a bewildering array of research-based and direct-to-consumer products available for use in the management of both pathologic and non-pathologic scars. This level of variation and complexity needs a more accurate and precise underlying organizational approach to unify research efforts and guide treatment choices. We see a need to develop a method of matching treatment to the specific scar of a specific patient at a specific time point in the scar’s maturation course.
Authors and Affiliations
Rahman Barry, Peter Ray, Hadiyah-Nicole Green
Keywords
Related Articles
- EP ID EP585842
- DOI 10.26717/BJSTR.2019.13.002362
- Views 137
- Downloads 0
Risk Factors Associated with Early Pregnancy and Attention Deficit Disorders
Introduction: early motherhood is a biological condition that is associated with neurological damage and when interacting with social, economic and environmental factors the susceptibility increases, favoring the develop...
Issues with Human Bioavailability Determinations of Bioactive Curcumin
The health benefits of curcumin which is extracted from turmeric (Curcuma longa) are well known. However, curcumin is poorly absorbed in the gastrointestinal tract and undergoes rapid metabolism to inactive forms. The fr...
easibility of Mitochondrial Transplantation Via Nose‐To‐Brain Delivery for Treatment of Parkinson Diseases
Olfactory dysfunction has been recently identified as one of the earliest non-motor symptoms of Parkinson’s disease (PD); it occurs at an early stage in approximately 90% of patients with PD and can be observed several y...
Clustering of Multiple Chronic Disease Risk Behaviors among Middle School Youth
Health-risk behaviors cluster or co-occur among youth populations [1-3], leading to increased risk for overweight/obesity and related chronic illnesses [4]. However, evidence specific to middle- school aged youth remains...
Successful Excision of a 15x20cm Giant Solitary Fibrous Tumor on Nape, Originating From Submesenchymal Cells
Objective: Solitary fibrous tumors are mostly benign tumors that originating from submesenchymal cells of parietal or, more commonly, visceral pleura.Case: In that case, we have hospitalized a male patient, who was atten...